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Effect of asymmetric dimethylarginine on osteoblastic differen- teopenia [1, 2]. The pathogenesis of adynamic bone dis-
tiation. ease is poorly understood. Indeed, this low turnover
Background. Asymmetric dimethylarginine (ADMA) is an bone disease cannot be explained entirely by the preva-endogenous inhibitor of nitric oxide synthase (NOS) that accu-
lence of factors known to impact upon bone physiologymulates in renal insufficiency and may be a uremic toxin. To
in uremia, such as parathyroid hormone (PTH), vitamindetermine whether ADMA inhibits bone metabolism, we in-
vestigated the in vitro effect of ADMA on osteoblastic differen- D treatment and aluminum accumulation. Rather, ady-
tiation in mouse bone marrow-derived mesenchymal stem cells namic bone disease is likely caused by additional alter-
(BMSCs). ations in the uremic milieu that are toxic to normal osteo-Methods. The effect of ADMA on nitric oxide (NO) produc-
blastic growth and development.tion was determined by measuring the stable end product of
Recent studies have implicated disruption of nitricNO, nitrite, in the culture medium using commercial NO kit.
The temporal sequence of osteoblastic differentiation in BMSCs oxide (NO) biosynthesis in the pathogenesis of uremia
was assessed in the presence and absence of ADMA by measur- [3, 4]. NO is a free radical synthesized from l-arginine by
ing alkaline phosphatase (ALP) activity, mineralization, and
NO synthase (NOS) group of enzymes. NO has diverseosteoblast gene expression at 0, 4, 8, 12 days of culture.
biological actions on the cardiovascular, immune, andResults. ADMA (5, 50, 500 mol · L1) resulted in a dose-
dependent decrease in nitrite formation in conditioned media central nervous systems that are predominantly medi-
of BMCS cultures, consistent with inhibition of NOS. ADMA ated by activation of cyclic guanine monophosphate
treatment was associated with reduced ALP activity, calcium (cGMP)-dependent intracellular cascades [5, 6]. Im-
deposition and osteoblast-related gene expression in BMSCs cul-
paired NO biosynthesis in renal failure is due to thetures. Concurrent treatment with l-arginine (3600 mol · L1)
accumulation of an endogenous inhibitor of NOS, asym-reversed the ADMA (500 mol · L1)-mediated decrease in
NO production, restored the differentiation potential of BMSCs, metric dimethylarginine (ADMA) [3, 4]. To date, inhibi-
and significantly attenuated the down-regulation of Cbfa1 and tion of NO elaboration secondary to accumulation of
osteocalcin gene expression by ADMA. ADMA has been implicated as an important pathogenic
Conclusions. ADMA inhibition of the NO-NOS pathway in
factor for arteriosclerosis, hypertension and macrophageBMSCs impairs osteoblastic differentiation of mouse BMSC
dysfunction in chronic renal failure [7–9].cultures. These studies further support a role of NO in the
local regulation of bone metabolism and the possibility that Several studies indicate that NO is an important signal-
ADMA may act as uremic toxin on bone through its effect to ing molecule involved in bone turnover. NO synthase
inhibit NO actions in osteoblasts. expression has been detected in vivo and in vitro in cells
of the osteoblastic lineage and in bone during fracture
healing in rats and humans [10, 11]. Endothelial nitric
Adynamic bone disease is a form of renal osteodystro- oxide synthase (eNOS) is the isoform most expressed
phy that is characterized by low bone turnover and os- in bone. NO is produced by osteoblasts in response to
cytokines, mechanical loading and estrogens [12–14]. In
cell culture, NO promotes the differentiation of clonal
Key words: nitric oxide, nitric oxide synthase, mesenchymal stem cells,
stromal cells (ST2 cells) derived from mouse bone mar-l-arginine, osteoporosis, end-stage renal disease, bone metabolism,
low turnover bone disease. row to osteoblast-like cells [15]. Targeted disruption of
the eNOS gene results in impaired osteoblast functionReceived for publication April 6, 2001
and osteopenia [16]. Suppression of NOS also impairsand in revised form June 18, 2001
Accepted for publication June 20, 2001 fracture healing, whereas supplementation of NO re-
verses the inhibition of healing produced by NOS inhibi- 2001 by the International Society of Nephrology
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tors [17–19]. Finally, chronic administration of l-arginine, cells was obtained by repeated aspiration of the cell
preparation through a 22-gauge needle, and nucleatedwhich increases NO production, decreases cyclosporine-
A–induced bone loss in rats [20]. cells were counted with a hemocytometer. Cells were
seeded into 12-well plates or 60 mm plates at a densitySince NO regulates osteoblast function and endoge-
nous inhibitors of NOS accumulate in renal failure raise, of 1 107 cells/mL and cultured for three days in -MEM
supplemented with 10% FBS, 100 kU · L1 of sodiumit is possible that inhibition of NOS and decrements in
NO by ADMA contributes to the osteoblast dysfunction penicillin G and 100 mg · L1 of streptomycin sulfate in
a humidified incubator with 5% CO2 and 95% air at aunderlying adynamic bone disease in ESRD. To begin
to address this possibility, we examined the effects of temperature of 37C. On day 3, all nonadherent cells were
then removed with the first medium change and thenADMA on osteoblastic growth and differentiation in
vitro. In the current investigations, we examined whether the adherent cells (representing bone marrow-derived
mesenchymal stem cells, BMSCs) were grown for addi-ADMA regulates NO release from osteoblasts, actively
affects growth and osteoblastic differentiation of bone tional periods of up 12 days in the differentiation medium
(-MEM containing 10% FBS supplemented with 5marrow mesenchymal stem cells (BMSCs), using alka-
line phosphatase (ALP) activity and matrix mineraliza- mmol · L1-glycerophosphate and 25g/mL of ascorbic
acid) for inducing osteoblastic differentiation of BMSCstion as markers, and regulates osteoblastic gene expres-
sion. For these studies, we used mouse primary BMSCs, [22]. In the time-course experiments, the beginning day
of culture in the differentiation medium was defined aswhich are capable of recapitulating the temporal se-
quence of osteoblasts maturation in culture. day 0. The ADMA (5, 50, 500 mol · L1) and ADMA
(500 mol · L1) concurrent with l-arginine (3600 mol ·
L1) treatment were added, respectively, and the me-
METHODS
dium was replaced every three days thereafter.
Reagents
Measurement of NO productionAlpha minimum essential medium (-MEM), Hanks’
balanced salt solution (HBSS), fetal bovine serum (FBS), Nitrite production in conditioned media (CM) was
measured as indirect measurement of NO productiontrypsin-ethylenediaminetetraacetic acid (EDTA), peni-
cillin-streptomycin solution, sodium dodecyl sulfate (SDS) using nitrite colorimetric assay kit by a modified Griess
assay [23]. Briefly, 100 L of CM or nitrite standards (0and Trizol Reagent were obtained from GIBCO BRL
(Grand Island, NY, USA). Pronase E, ascorbic acid, -gly- to 100 mol · L1) were mixed with 100 L of Griess
reagent. Absorbance was then measured at 530 nmcerophosphate, p-nitrophenol, diethanolamine, p-nitro-
phenol phosphate, asymmetric dimethylarginine, l-argi- against a blank prepared with non-conditioned medium,
and the release of NO into the culture medium wasnine, alizarin red-S, and calcium kit for the measurement
of calcium content were purchased from Sigma Chemical expressed as nitrite concentration, which was determined
from a standard curve.Co. (St. Louis, MO, USA). Tissue culture plastic wares
were purchased from Corning-Costar Co. (Corning Co-
Alkaline phosphates activitystar, NY, USA). Nitrate/nitrite colorimetric assay kit
was purchased from Jingmei Biotech Co. Ltd (Shenzhen, Cellular alkaline phosphates (ALP) activity was as-
sayed according to our previous study [22]. At the com-China). Molecular biology reagents and enzymes were
purchased from Boehringer Mannheim (Indianapolis, pletion of the incubation period, cells were harvested
by removing the media, washing twice with HBSS, andIN, USA). TaKaRa RNA PCR kit (AMV) version 2.1
was purchased from TaKaRa Biotechnology Co, Ltd treating for 10 minutes with 0.25% trysin-1 mmol · L1
EDTA to achieve cell detachment. Cell number was(Dalian, China). Bio-Rad reagent for protein assay was
obtained from Bio-Rad Laboratories (Hercules, CA, determined by direct counting with a hemocytometer,
and enzyme activity was determined colorimetrically us-USA). All other chemicals were of analytical grade and
from Shanghai Biotech Co. Ltd (Shanghai, China). ing p-nitrophenylphosphate as the substrate at pH 10.3
and reading the optical density at 400 nm. ALP activity
Cell culture is expressed as nmol p-nitrophenol formed/min/104 cells
assuming 1 A410 64 nmol product.Bone marrow cells were obtained from 8- to 10-week-
old female mice of the Kunming strain (the Experimental
Quantitation of calcium depositionAnimal Center, Xiangya Medical College, Central South
University, Changsha, China) as previously described Calcification of BMSCs was assessed by a modification
of the Wada procedure [24]. The cultures were decalci-[21]. Briefly, the femurs and tibias were dissected, the
ends of the bones were cut, and marrow was flushed out fied with 0.6 N HCl for 24 hours. The calcium content
was determined by measuring the concentrations of cal-with 2 mL of ice-cold -MEM containing 10% FBS by
using a needle and syringe. A suspension of bone marrow cium in the HCl supernatant by the o-cresolphthalein
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complexone method. After decalcification, the cultures
were washed with HBSS and solubilized with 0.1 N
NaOH/ 0.1% SDS. Total protein content was measured
with a Bio-Rad protein assay kit. The calcium content
of the cell layer was normalized to protein content.
Detection of bone nodules
Bone marrow cells were grown in 12-well plates for
12 days with an initial seeding density of 1 107 cells/mL,
in which the media contains ascorbic acid and -glycero-
phosphate. Cultures were fixed for 24 hours in 1:1:1.5
solutions of 10% Formalin, methanol, and water. Bone
nodules were detected using a calcium-specific dye Aliza-
rin Red (pH 4.0) staining, as previously described [15, 25].
Fig. 1. Dose response of asymmetric dimethylarginine (ADMA) onBone nodules per well were counted macroscopically.
the inhibition of nitric oxide (NO) production of conditioned medium
in mouse bone marrow-derived mesenchymal stem cell (BMSC) cul-RT-PCR analysis tures. The mouse BMSCs were cultured in the differentiation medium
in the absence (control) or in the presence of graded dosages of 5 toTotal RNA was isolated from the BMSCs cultured in
500 mol · L1 ADMA for 0, 4, 8, and 12 days. The culture media were
60 mm plates by the single-step method using Trizol collected and NO levels were analyzed using nitrite colorimetric assay
reagent, as previously reported [22]. RNA samples were kit by a modified Griess assay at different time points. Values are the
mean  SEM of two experiments in triplicate. *P 	 0.05; **P 	 0.01pretreated with DNase to remove any contaminating
vs. control. Symbols are () control; () 5 mol · L1 ADMA; () 50
DNA and were quantified by absorbance at 260 nm. mol · L1 ADMA; () 500 mol · L1 ADMA.
Reverse transcription-polymerase chain reaction (RT-
PCR) was done using TaKaRa RNA PCR kit (AMV)
version 2.1. One microgram of total RNA was reverse-
of different time points, consistent with inhibition oftranscribed into cDNA using the reverse primer. The
NOS (Fig. 1). To further demonstrate the l-arginine:NORT reaction was incubated at 42C for 30 minutes. PCR
pathway in the role of ADMA, l-arginine was employed.was performed with thermal cycling parameters of 94C
As expected, the l-arginine (3600mol · L1) completelyfor 45 seconds, 60C for 45 seconds, 72C for 90 seconds
abolished the inhibition of NO production by ADMAfor 30 cycles following by a final extension at 72C for
(500 mol · L1) in the conditioned media at day 127 minutes. Primers for mouse Cbfa1, osteocalcin, and
(Table 1). Thus, the effect of ADMA on BMSC cultures-actin were synthesized as follows: Cbfa1 primer (sense):
was dependent on the ratio of ADMA to l-arginine in5
-AGGACAGAGTCAGATTACAG-3
; Cbfa1 primer
the media.(antisense): 5
-TCAATATGGCCGCCAAACAG-3
; os-
The effect of ADMA (5 to 500 mol · L1) on mouseosteocalcin primer (sense): 5
-CAAGTCCCACACAG
BMSC growth was assayed at different time points, andCAGCTT-3
; osteocalcin primer (antisense): 5
-AAAG
the number of cells in response to high concentration ofCCGAGCTGCCAGAGTT-3
; -actin primer (sense):
ADMA (500mol · L1) was a slight but not significantly5
-GTGGGCCGCTCTAGGCACCA-3
; -actin primer
increased when compared with control (data not shown).(antisense): 5
-CGGTTGGCCTTAGGGTTCAGGGG
However, ADMA inhibited osteoblastic differentiationGG-3
.
of mouse BMSCs in a dose-related manner, as evaluated
Statistical analysis by the ALP activity in the primary cultures at different
time points, the inhibition being statistically significant atAll values were expressed as mean values  SEM.
50 mol · L1 (Fig. 2). Similarly, co-incubation of l-argi-Statistical analysis was carried out by analysis of variance
nine (3600 mol · L1) with ADMA (500 mol · L1)and the Newman-Keuls test. A P value	0.05 was consid-
completely restored the osteoblastic differentiation po-ered statistically significant.
tential of BMSCs, as evidenced by a significant increase
of ALP activity when compared with ADMA-treated
RESULTS group in the BMSC cultures at day 12. l-arginine (3600
mol · L1) alone had no effect on ALP activity (Table 1).To determine whether ADMA has any effect on the
NO levels, the mouse primary BMSCs were incubated The calcium deposition in mouse BMSC cultures was
induced by ascorbic acid and -glycerophosphate in awith increasing concentrations of ADMA for 0, 4, 8, and
12 days, and then the NO released into the culture media time-dependent manner. As expected, the calcium depo-
sition in BMSC cultures was dose-dependently inhibitedwas measured. ADMA resulted in a dose-dependent
decrease in the production of NO in conditioned media by the exposure to ADMA (Fig. 3). The effect of ADMA
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Table 1. Effect of l-arginine on the inhibition of nitric oxide (NO) production and osteoblastic phenotype markers by asymmetric
dimethylarginine (ADMA) in mouse bone marrow-derived mesenchymal stem cells (BMSCs) cultures
Nitrite ALP activity Calcium deposition Bone nodules formation
Groups lmol · L1 nmol/min 104 cells lg/lg protein nodules/well
Control 69.91.1a 6.870.24a 0.590.02a 321.3a
ADMA 500 lmol · L1 54.81.7 4.900.12 0.420.01 171.6
l-arg 3600 lmol · L1 69.22.2a 6.760.26a 0.610.03a 311.7a
ADMA  l-arg 65.11.8a 6.780.32a 0.580.02a 281.5a
The mouse BMSCs were cultured in the differentiation medium in the absence (control) or in the presence of 500 mol · L1 ADMA, or 3600 mol · L1
l-arginine, or ADMA plus l-arginine for 12 days. The culture media, aliquots of total cell lysates, the HCl supernatant of cell layer extract and alizarin red staining
of cell cultures were tested for nitrite levels, alkaline phosphatase (ALP) activities, calcium content and bone nodules formation at day 12 as described in the Methods
section. Values are the mean  SEM of two experiments in triplicate.
aP 	 0.001 compared with ADMA treatment as assessed by analysis of variance and the Newman-Keuls test
Fig. 2. Dose response of ADMA on the inhibition of alkaline phos-
phates (ALP) activity in mouse BMSC cultures. Mouse BMSCs were
Fig. 3. Dose response of ADMA on the inhibition of calcium depositioncultured in the differentiation medium in the absence (control) or in
in mouse BMSC cultures. Mouse BMSCs were cultured in the differenti-the presence of graded dosages of 5-500 mol · L1 ADMA for 0, 4,
ation medium in the absence (control) or in the presence of graded8, and 12 days. The cellular ALP activity was assayed colorimetrically
dosages of 5 to 500 mol · L1 ADMA for 0, 4, 8, and 12 days. Theusing p-nitrophenylphosphate as the substrate. ALP activity was ex-
calcium content was determined by measuring the concentrations ofpressed as nmoles of p-nitrophenol formed per minute of 104 cells at
calcium in the HCl supernatant by the o-cresolphthalein complexonedifferent time points. Values are the mean  SEM of two experiments
method at different time points. Values are the mean  SEM of twoin triplicate. *P 	 0.05; **P	 0.01 vs. control. Symbols are () control;
experiments in triplicate. *P 	 0.05; **P 	0.01 vs. control. Symbols() 5 mol · L1 ADMA; () 50 mol · L1 ADMA; () 500 mol ·
are () control; () 5 mol · L1 ADMA; () 50 mol · L1 ADMA;L1 ADMA.
() 500 mol · L1 ADMA.
on mineral deposition was even more evident when Ali-
than in control cultures, as demonstrated by ethidiumzarin Red staining was used to visualized bone nodules
bromide-stained agarose gel (Fig. 4). l-arginine also sig-on day 12, especially at high concentration (Table 1). In
nificantly reversed the down-regulation of Cbfa1 andcontrast, coadministration of l-arginine (3600 mol ·
OSC genes by ADMA when 3600 mol · L1 l-arginineL1) with ADMA (500 mol · L1) achieved a statisti-
was added with 500 mol · L1 ADMA into the culturecally significant increase in calcium deposition and bone
nodules in the cultures for 12 days; l-arginine alone had medium. l-arginine alone had no effect on osteoblastic
no effect (Table 1). gene expression (Fig. 4).
RT-PCR analysis was performed to evaluate further
the effect of ADMA on the expression of mRNA for
DISCUSSIONCbfa1 and osteocalcin (OSC), as a marker for the osteo-
This study utilized mouse BMSCs to test the hypothesisblastic differentiation, in BMSC cultures at day 12. The
that ADMA can impair osteoblastic function throughlevel of -actin mRNA was analyzed in the same samples
inhibition of NO synthesis. Bone marrow-derived mes-as a housekeeping reference gene. When compared to
enchymal stem cells (BMSCs) are a population of pluri-the level of -actin mRNA, the relative levels of Cbfa1
potent cells within the bone marrow microenvironmentand OSC mRNA levels were significantly lower in the
cultures grown in the presence of 500 mol · L1 ADMA defined by their ability to differentiate into various cell
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resulted in the down-regulation of osteoblast-specific
gene expression. Cbfa1, a transcription factor that has
an important role in osteoblast phenotype and related
genes’ expression [29, 30], was inhibited by ADMA, con-
cordant with its effect to impair osteoblastic differentia-
tion. Osteocalcin also was inhibited after ADMA treat-
ment. Furthermore, cotreatment of mouse BMSCs with
l-arginine and ADMA blunted the decrease in Cbfa1
and osteocalcin mRNA, respectively. Our studies did
Fig. 4. Expression of Cbfa1, osteocalcin, and -actin mRNA in mouse not investigate the signal transduction events mediating
BMSCs treated with ADMA and L-arginine for 12 days. Total RNA these effects. Because soluble guanylyl cyclase (sGC)
was isolated from the BMSCs cultured for 12 days by the single-step
catalyzes cGMP synthesis and serves as a physiologicalmethod using Trizol reagent. RT-PCR amplification of Cbfa1 (727 bp),
osteocalcin (370 bp) and -actin (245 bp) was carried out using 1 g receptor for NO, it is possible that ADMA’s inhibition
total RNA and gene-specific primers. PCR products of 30 cycles were of osteoblastic gene expression is mediated by reduced
run and separated by 1.7% agarose gel. Lanes are: lane M, 100 bp DNA
stimulation of cGMP-dependent pathways [5, 6]. Cur-ladder; lanes 1, 3, 5, and 7, the absence of RT vs. lanes 2, 4, 6, 8. Lane
2 shows the presence of RT; lane 4 is Control, lane 6 is ADMA 500 rently, no studies have examined the effect of cGMP on
mol · L1; lane 8 is l-arginine 3600 mol · L1; and lane 8 is ADMA Cbfa1 gene expression; however, recently the guanylate
l-arginine.
cyclase inhibitor ODQ has been shown to block NO-
stimulated osteoblast differentiation [31]. Prostaglandin
pathways also could be involved, since NO stimulated
prostaglandin E production in ST2 cells by mechanismslineages, including osteoblasts, chondrocytes, and adipo-
cytes, when placed in appropriate in vitro and in vivo en- not involving cGMP synthesis [15]. Further studies are
needed to determine the molecular whereby mechanismsvironments [26, 27]. The results of our experiments dem-
onstrate that incubation of mouse BMSCs with ADMA of ADMA and NO dependent pathway regulate osteo-
blastic gene expression.leads to a dose-dependent decrease in NO formation,
consistent with inhibition of NOS. We also show that the Nevertheless, our findings have several potential im-
plications. First, they support the possibility that accumu-inhibition of NOS was associated with a reduction in ALP
activity, calcium deposition, and bone nodule formation lation of these endogenously produced asymmetrically
methylated arginines in ESRD could modulate NO pro-of BMSCs cultures. The NOS inhibitor L-NMMA (103
mol · L1) is reported to have similar inhibitory effects duction and bone cell function. While our study found
no significant difference in cell proliferation, there wereon osteoblast function in some [18, 28] but not other
studies [13]. Collectively, these data indicate that osteo- differences in the maturation of cells between ADMA
and control groups. The effect could be the result ofblasts express NOS enzymes and produce NO, whose
physiological functions are to regulate osteoblast lineage delayed maturation and/or decreased function of osteo-
blasts. Whether chronically elevated ADMA levels ofcommitment, differentiation and maturation from BMSCs,
and postnatal bone formation. the magnitude observed in ESRD are associated with
impaired osteoblast function and adynamic bone diseaseThe levels of ADMA in culture required to achieve
these results are considerably higher than what has been will need to be established by clinical studies. Based on
our findings, however, such investigations appear to bereported in the circulation of patients with ESRD [3]. It
is likely that high concentrations of ADMA, namely justified. Second, we demonstrated that ADMA inhibi-
tion of NO production was competitively overcome by50 to 500 mol/L, are needed in culture to offset the
correspondingly high 600 mol/L l-arginine concentra- increasing the l-arginine concentration in culture media,
which restored NO production rates and osteoblastiction in the culture media. In ESRD, the pathologically
high levels of ADMA of 10 mol/L is in the setting of differentiation potential of mouse BMSC cultures. There
are likely many factors involved in the pathogenesis ofa l-arginine concentrations of 75 mol/L. Thus, the ratio
of l-arginine/ADMA of 12 to 1.2 that leads to a signifi- adynamic bone disease. Our findings suggest that one of
these may be ADMA accumulation and the resultingcant effect in our cell culture study approximates the
ratio of l-arginine/ADMA of 7.5 that is found in the inhibition of nitric oxide synthase in osteoblasts. Whether
the administration of arginine could have similar promis-serum of patients with ESRD. Thus, the higher ADMA
levels in vitro are appropriate for the level of l-arginine ing effects on bone formation in ESRD and adynamic
bone disease needs to be studied in prospective trials.in the media. In addition, we cannot exclude the possibil-
ity that other uremic toxins or cofactors enhanced the Finally, our studies suggest the need to investigate the
potential role of ADMA in other conditions associatedeffect of ADMA in ESRD or that osteoblasts might more
susceptible to ADMA’s effects compared to BMSCs. with impaired osteoblast function, including age-related
bone loss. In this regard, raloxifene, a selective estrogenOur studies also demonstrate that inhibition of NO
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nitric oxide synthase isoforms in bone and bone cell cultures. J Bonereceptor modulator (SERM) that prevents postmeno-
Miner Res 12:1108–1115, 1997
pausal osteoporosis, stimulates release of NO from endo- 11. Hukkanen MV, Platts LAM, Fernandez de Marticorena I, et
al: Developmental regulation of nitric oxide synthase expressionthelial cells.
in rat skeletal bone. J Bone Miner Res 14:868–877, 1999In conclusion, our results indicate that ADMA inhibits
12. Hikiji H, Shin WS, Oida S, et al: Direct action of nitric oxide on
the NO-NOS pathway in BMSCs and might impair their osteoblastic differentiation. FEBS Lett 410:238–242, 1997
13. O’Shaughnessy MC, Polak JM, Afzal F, et al: Nitric oxide medi-differentiation into osteoblasts. These studies further
ates 17beta-estradiol-stimulated human and rodent osteoblast pro-support a role of NO in the local regulation of bone
liferation and differentiation. Biochem Biophys Res Commun 277:
metabolism and point to the accumulation of ADMA 604–610, 2000
14. Simoncini T, Genazzani AR: Raloxifene acutely stimulates nitricas a possible factor in the pathogenesis of low turnover
oxide release from human endothelial cells via an activation ofbone diseases.
endothelial nitric oxide synthase. J Clin Endocrinol Metab 85:2966–
2969, 2000
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